



July 25, 2023

**BSE Limited**  
Floor 25, P. J. Towers  
Dalal Street, Fort  
Mumbai - 400 001

**National Stock Exchange of India Limited**  
Exchange Plaza  
Bandra Kurla Complex  
Bandra (E), Mumbai - 400 051

Scrip Code: **543271**

Trading Symbol: **JUBLINGREA**

Dear Sirs,

**Sub: Schedule for Investor Conference Call for Jubilant Ingrevia Limited – Unaudited Financial Results for the quarter ended June 30, 2023**

In continuation to intimation dated July 17, 2023, we wish to inform you that the date of Conference Call stands changed from Wednesday, July 26, 2023 to Thursday, July 27, 2023.

Please take the same on record.

Thanking you

Yours faithfully,

For Jubilant Ingrevia Limited

Deepanjali Gulati  
Company Secretary

Encl.: as above

A Jubilant Bhartia Company

OUR VALUES



**Jubilant Ingrevia Limited**

1-A, Sector 16-A,  
Noida-201 301, UP, India  
Tel: +91 120 4361000  
Fax: +91 120 4234895-96  
[www.jubilantingrevia.com](http://www.jubilantingrevia.com)

Regd Office:  
Bhartiagram, Gajraula  
Distt. Amroha - 244 223  
Uttar Pradesh, India  
CIN : L24299UP2019PLC122657




Noida, Tuesday, July 25, 2023

---

**Conference call on Thursday, July 27, 2023 at 05:00 pm IST**

---

The management team of Jubilant Ingrevia Limited (JVL) – an integrated global Life Science products and Innovative Solutions provider company, will host its conference call for analysts and investors on Wednesday, July 27, 2023 at 05:00 pm IST. The call will commence with a brief management discussion on the financial performance for the quarter ended June 30, 2023, followed by an interactive Question & Answer session.

Diamond Pass Log-In	
<b>Pre-registration:</b>	To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link.  <a href="#">Click here to ExpressJoin the Call</a>
	You will receive dial in numbers, passcode and a pin for the concall on the registered email address provided by you. Kindly dial into the call on the Conference Call date and use the passcode & pin to connect to call.
<b>Conference Dial-In Numbers</b>	
Universal Access:	+ 91 22 6280 1141 + 91 22 7115 8042
Toll Free Number:	USA: 1 866 746 2133 UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448
Audio Link:	The Audio link will be available on the company website. Please access the link here - <a href="https://jubilantingrevia.com/investors/financials/quarterly-results">https://jubilantingrevia.com/investors/financials/quarterly-results</a>

-ENDS -

---

## **About Jubilant Ingrevia Limited**

*Jubilant Ingrevia Limited is a global integrated Life Science products and Innovative Solutions provider serving Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with customised products and solutions that are innovative, cost-effective, and conforming to excellent quality standards.*

*The Company offers a broad portfolio of high-quality ingredients that find application in a wide range of industries. The company has over 2,300 employees and serves more than 1,500 customers in more than 50 countries across the world. The Company's portfolio also extends to custom research and manufacturing for pharmaceutical and agrochemical customers on an exclusive basis.*

*Jubilant Ingrevia is a Responsible Care certified company, driven by the motive to add value to millions of lives through innovations and cutting-edge technology. As a leader in key products that the Company manufactures, it takes pride in being a partner of choice for its valued customers.*

For more information, please visit: [www.jubilantingrevia.com](http://www.jubilantingrevia.com).

---

### **For more information please contact:**

---

Pavleen Taneja

Jubilant Ingrevia Limited

Ph: +91-120 4361000

E-mail: [pavleen.taneja@jubl.com](mailto:pavleen.taneja@jubl.com)

Siddharth Rangnekar / Mit Shah

CDR India

Ph: +91 97699 19966 / 99201 68314

E-mail: [siddharth@cdr-india.com](mailto:siddharth@cdr-india.com)  
[mit@cdr-india.com](mailto:mit@cdr-india.com)

**Disclaimer:** *Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Ingrevia Limited may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.*

---

---